Amgen and Pfizer Top Market Capitalization Lists in Genetic Engineering News.Business Editors & Health/Medical Writers BIOWIRE2K LARCHMONT, N.Y.--(BW HealthWire)--June 3, 2002 Amgen (Nasdaq:AMGN) is the number one biotechnology company in terms of market capitalization while Pfizer (NYSE NYSE See: New York Stock Exchange :PFE) holds down the top spot among pharmaceutical firms in Genetic Engineering News' (GEN) annual feature, "Top 50 Biofirms and 10 Leading Drug Companies." Genentech (NYSE:DNA DNA: see nucleic acid. DNA or deoxyribonucleic acid One of two types of nucleic acid (the other is RNA); a complex organic compound found in all living cells and many viruses. It is the chemical substance of genes. ) and Serono (NYSE:SRA) follow Amgen in that order, and Johnson & Johnson (NYSE:JNJ) and GlaxoSmithKline (NYSE:GSK) come in after Pfizer, according to the June 1 issue of GEN (www.genengnews.com). "Despite a recession, a closed IPO (Initial Public Offering) The first time a company offers shares of stock to the public. While not a computer term per se, many founders, employees and insiders of computer companies have found this acronym more exciting than any tech term they ever heard. window and the lingering aftereffects aftereffects after npl → Nachwirkungen pl of 9/11, biotech and pharmaceutical companies are moving forward with their R&D and product development plans," says John Sterling, managing editor of GEN. "Nevertheless, our listings do show how the economy and Wall Street have impacted industries." In looking at this year's market caps, for example, Amgen ($52.28 billion), Genentech ($18.53B) and Serono ($17.97B) are all down from the numbers in 2001 ($68.71B, $26.85B, and $21.85B, respectively). Among the pharmaceutical firms, Pfizer ($234.1B vs. $264.3B last year) and GlaxoSmithKline ($148.6B vs. $167.4B in 2001) follow the biotech trend. However, Johnson & Johnson, with a 2002 market cap of $195.6B, grew appreciably from last year's $135.9B.). Among a number of other biotech companies published in GEN's market cap listing are Immunex (Nasdaq:IMNX), $14.26B; Genzyme (Nasdaq:GENZ), $8.44B; Idec Pharmaceuticals (Nasdaq:IDPH IDPH Illinois Department of Public Health IDPH Iowa Department of Public Health ), $8.03B; MedImmune (Nasdaq:MEDI MEDI Marine Environmental Data Information Referral System ), $7.89B; Chiron (Nasdaq:CHIR CHIR Chiricahua National Monument (US National Park Service) ), $7.39B; Gilead Sciences (Nasdaq:GILD), $6.38B; and Biogen (Nasdaq:BGEN), $6.17B. Merck & Co. (NYSE:MRK), $126.2B; Novartis (NYSE:NVS), $106.5B; Abbott Labs (NYSE:ABT), $84.1B; AstraZeneca (NYSE:AZN), $81.5B; Wyeth (NYSE:WYE), $78.6B; Eli Lilly (NYSE:LLY), $76.4B; and Bristol-Myers Squibb (NYSE:BMY), $56.9B, comprise the rest of the pharmaceutical firm market cap listings. Genetic Engineering News is published 21 times a year by Mary Ann Liebert Inc. For a copy of the April 1 issue featuring "Molecular Millionaires," please call 914/834-3100, ext 623, or e-mail: ebicovny@liebertpub.com. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion